ADT Inc/ US00090Q1031 /
| 3/1/2021 9:59:52 PM | Chg. +0.14 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 7.76USD | +1.77% | 194,307 Turnover: 1.5 mill. |
-Bid Size: - | -Ask Size: - | 7.85 | 7.48 |
GlobeNewswire
3/1
Veru Receives FDA Agreement to Advance VERU-111 into Phase 3 Study in Hospitalized COVID-19 Patients...
GlobeNewswire
2/24
XPO Logistics Names Treasurer Ravi Tulsyan to Additional Role as Deputy Chief Financial Officer
GlobeNewswire
2/23
DirectTrust Announces Implementation Guide for Event Notifications via the Direct Standard™
GlobeNewswire
2/18
ADT and Hippo Partner to Add Professionally Installed and Monitored Smart Home Services and Discount...
GlobeNewswire
2/11
ADT To Release Fourth Quarter and Full Year 2020 Results On Thursday, February 25, 2021
GlobeNewswire
2/11
TELUS reports operational and financial results for fourth quarter 2020; announces 2021 consolidated...
GlobeNewswire
2/10
Veru Sets Another Quarterly Record in Both Net Revenues and in Gross Profit for Fiscal 2021 First Qu...
GlobeNewswire
2/8
An Alternative Nationwide Health Information Network Has Launched to Scale and Solve National Intero...
GlobeNewswire
2/8
Veru Reports Positive Phase 2 Clinical Results of VERU-111 in Hospitalized COVID-19 Patients at High...
GlobeNewswire
1/19
Veru Announces Nature Medicine Publication Demonstrating that Enobosarm, an Androgen Receptor Target...
GlobeNewswire
1/4
Veru to Present at the H.C. Wainwright Bioconnect 2021 Conference on January 11th, 2021
GlobeNewswire
12/14/2020
Veru Reports Positive Phase 2 Clinical Trial Results for Enobosarm, Selective Androgen Receptor Targ...